Combination therapy
Combination therapy is the use of two or more therapeutic agents, treatment modalities, or biologically distinct interventions to address a disease simultaneously.
Combination therapy is the use of two or more therapeutic agents, treatment modalities, or biologically distinct interventions to address a disease simultaneously. The components may be administered together or in sequence and can act through complementary mechanisms, such as direct cytotoxicity, immunotherapy, inhibition of signaling pathways, antiviral activity, anticoagulation, or modulation of the tumor microenvironment. Combination therapy is commonly contrasted with monotherapy, in which a single intervention is used.
The intended effects of combination therapy may include additive or synergistic therapeutic efficacy, broader control of disease biology, and circumvention of treatment resistance. In cancer research, combinations may involve cytotoxic drugs, checkpoint inhibitors, targeted agents, antiangiogenic treatment such as bevacizumab, or agents directed at pathways involving vascular endothelial growth factor, apoptosis, ferroptosis, macrophage activity, or transforming growth factor signaling. Assessment of a combination may include tumor control, survival, toxicity, cell viability, and mechanistic assays such as flow cytometry. However, the biological interaction between components can vary substantially across diseases and treatment regimens; the literature represented here spans neurological disease, cancer, viral pneumonia, leukemia, and mathematical modeling rather than forming a single disease-specific therapeutic program.
Rebuilt from PubMed 18 Sept 2026 · no new papers today
Where the papers sit
17 papers study combination therapy directly. Those 17 do not group into themes. Combination approaches span cancer, inflammatory disease, neurology, infection, and antibiotic resistance, using computational discovery, trials, animal models, and real-world data. No shared biological question or consistent therapeutic direction emerges. They are no more alike than papers drawn from anywhere in the corpus. 1 new direction follows.
Combination therapy becomes a dynamical-systems control problem rather than only a treatment regimen
The tumor–immune model incorporating immune checkpoint inhibitors and CCR2 antagonists treats combination therapy not simply as a regimen to be tested for improved tumor control, but as a parameterized intervention that can generate transcritical, saddle-node, and cusp bifurcations, alter multistability, and determine quantitative conditions for alternative tumor equilibria. This gives combination therapy a distinct role as a tool for analyzing and controlling the qualitative dynamics of tumor–immune systems, beyond the set’s usual uses of enhancing efficacy, overcoming resistance, or prioritizing drug pairs 42562918Aug.
Recent Findings on combination therapy
Drug Development Across Diseases: Drug pairs and multidrug regimens improve therapeutic efficacy by combining pathway inhibition, immune activation, antiviral activity, anticoagulation, or resistance reversal across diseases 42748134Sep42684552Sep42686681Sep42281209Jun. Computational screens and mechanistic models increasingly prioritize combinations before testing, using LWAS, GRR, MNRS, virtual tumors, and bifurcation analysis to identify synergistic, patient-specific, or potentially incompatible regimens 42748134Sep42727586Sep42562918Aug42341181Jun. Preclinical and clinical results often favor combinations over monotherapy, including Trop-2 ADC regimens in metastatic triple-negative breast cancer, pembrolizumab plus metformin, perioperative targeted immunotherapy plus TACE, and metformin plus empagliflozin in rotenone-induced Parkinsonism 42714605Sep42347882Jun42015536Apr42711364Sep. Responses remain context-dependent because MNRS identifies incompatible drug pairs, tumor control depends on initial tumor burden and dose, and some combinations match rather than exceed a stronger monotherapy 42727586Sep42562918Aug42711364Sep. The field is moving toward biomarker-guided and response-guided treatment, with genomic scoring, single-cell analysis, patient-derived signatures, and prospective validation guiding combination selection 42714605Sep42727567Sep42341181Jun.
Written from 17 PubMed abstracts, each one cited by PMID above. Published: 2026-09-10. Last written: 2026-09-18 by GPT. Drafted by language models from published abstracts; not medical advice.